-
平臺(tái)編號(hào)：bio-69063
-
國(guó)際編號(hào)：HB-10611?
-
細(xì)胞信息： 1H11
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
1H11
ATCC Number：HB-10611?
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
細(xì)胞形態(tài)：淋巴樣
免疫類(lèi)型：IgG1
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
規(guī)格：0.5mg Designations: 1H11
Depositors: ?Washington Research Foundation
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against bone type 1 collagen amino terminal telopeptide
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with a conjugate of keyhole limpet hemocyanin (KLH) and a telopeptide having a 3-hydroxypyridinium crosslink derived from the amino terminal domain of bone type I collagen.
Spleen cells were fused with mouse myeloma cells.
The antibody can be used to detect and quantitate degradation products of bone type I collagen in body fluids.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
References: 22055: Eyre DR. Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide. US Patent 5,300,434 dated Apr 5 1994
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
細(xì)胞形態(tài)：淋巴樣
免疫類(lèi)型：IgG1
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
規(guī)格：0.5mg Designations: 1H11
Depositors: ?Washington Research Foundation
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against bone type 1 collagen amino terminal telopeptide
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with a conjugate of keyhole limpet hemocyanin (KLH) and a telopeptide having a 3-hydroxypyridinium crosslink derived from the amino terminal domain of bone type I collagen.
Spleen cells were fused with mouse myeloma cells.
The antibody can be used to detect and quantitate degradation products of bone type I collagen in body fluids.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
References: 22055: Eyre DR. Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide. US Patent 5,300,434 dated Apr 5 1994
